Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event - Wikidata - awgldk - TriplyDB

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event

http://www.wikidata.org/entity/Q28320362

about

sameAs

An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014 AMD3100/CXCR4 Inhibitor 4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100 Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding: effect on virus-cell fusion but not on cell-cell fusion Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. A basis for anti-HIV drug design Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells Characterization of human immunodeficiency virus type 1 resistant to modified cyclodextrin sulphate (mCDS71) in vitro Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4 SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.Protein recognition of macrocycles: binding of anti-HIV metallocyclams to lysozyme.Novel compounds in preclinical/early clinical development for the treatment of HIV infections.env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors.An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.New anti-HIV agents and targets.HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4.Chemokine receptors: emerging opportunities for new anti-HIV therapies.G protein-coupled receptors--recent advances Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry.Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120.Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.Antiviral therapy for human immunodeficiency virus infections Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors.Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).Blockade of hypoxia-induced CXCR4 with AMD3100 inhibits production of OA-associated catabolic mediators IL-1β and MMP-13 Binding optimization through coordination chemistry: CXCR4 chemokine receptor antagonists from ultrarigid metal complexes.Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.Chemokine receptor antagonists: part 2.Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study.Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.

P2860

Q26771734-DF891824-D9A2-474D-AAD6-91F67E8F69A6 Q28087445-4CB2BCBE-F387-450B-9635-C6F550D60CF6 Q28362567-11524B4C-91C0-49CE-8C68-B1CD719EF909 Q28368978-B6CF72FE-6155-45BD-9B86-8543E72E3549 Q28369127-62896BFD-AA5C-4D38-BFAB-6F2DBF0A3330 Q28369425-A2B28BE5-6B93-4EBE-992E-11E2ABE60FB1 Q28369657-36C11D9C-E536-461A-B5C6-59D4C7CA96B4 Q28371764-468024C1-3E1F-4864-BE95-57CC89938CEA Q28378745-9F86A315-7C37-427C-B3DE-4AC38A224163 Q28378759-5512B978-58A2-4B36-A346-982D46908DB2 Q28379182-CDFE1355-4695-4FC9-A1E1-DCF2EB23D114 Q28379459-1678B96D-546F-4F87-B4FC-59273823D29C Q28379465-B81000DA-8958-41AD-A7A2-8622CC876D6E Q30832371-14D0FDED-820E-4808-8612-FCFF50C3C13C Q33559560-94BBD0C7-5A15-4899-B968-4B696BB7A792 Q33677057-CBE6D977-7F5F-420A-9662-230F8900F96A Q33850234-8A7DAE80-ED4D-42C3-86E7-5E909A536942 Q33966254-D1FF490A-3F07-4F93-A611-716F67384EA9 Q34253200-8AA0CEE0-1202-4D17-BF70-4280762478E3 Q34351378-5A5A3165-287E-4151-A665-16A3BB2802C4 Q34569177-EFC0BF0E-D6BA-4843-931B-28BD034B63AB Q34944447-F7EA600F-B9F3-4494-A32F-A25267F630DE Q34976806-9518DA13-AB85-4952-8BBF-FD81950CBDE1 Q35050395-C22F5772-CBFB-4013-A8D0-4122669B4060 Q35065927-4D48761C-1628-4AD6-9B0E-DBE0A5B84AAF Q35123263-FCEF28FE-C2A6-48D1-9915-8E9A30BAEA54 Q35139301-2104E756-C4E7-4AED-B33C-9ED9178EA890 Q35213463-79FFFA8C-B039-42D7-991E-864D1A2474C2 Q35366050-8B1DBFE5-ECDC-497C-B240-7F35D9B6AF1B Q35636068-07D80504-035E-4256-B103-25C2DF98B8D2 Q36094966-D298FBD4-E828-4A03-8FD0-01FD780F85BE Q36181360-576CCFD3-D5E5-47C7-B2DE-80F041AF3D85 Q36334083-DD3D3CC5-8911-4C87-B3E1-992DF9B64E86 Q37082987-CA4BC0A4-E604-416A-A2D3-9EBA59EC62B6 Q37187072-5B0A294A-B8F0-4F9C-88E4-12C4A99C482F Q37337280-31CB476F-30CA-4174-9111-5B0A0E0C06C7 Q37481304-45228BE1-33C8-4A99-9309-2EB19FD6BECE Q37596456-8CD6EF3B-E267-4709-BDB8-2469E5947272 Q37686164-B06FA05E-CBDF-4AD9-9CDF-378B2DF22BDD Q37866794-C64BAE9E-A87C-4932-B02C-9CC36252AA97

P2860

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event

http://www.wikidata.org/entity/Q28320362

description

1992 nî lūn-bûn

@nan

1992 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1992 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1992年の論文

@ja

1992年論文

@yue

1992年論文

@zh-hant

1992年論文

@zh-hk

1992年論文

@zh-mo

1992年論文

@zh-tw

1992年论文

@wuu

name

Potent and selective inhibitio ...... g with a viral uncoating event

@ast

Potent and selective inhibitio ...... g with a viral uncoating event

@en

Potent and selective inhibitio ...... g with a viral uncoating event

@nl

type

label

Potent and selective inhibitio ...... g with a viral uncoating event

@ast

Potent and selective inhibitio ...... g with a viral uncoating event

@en

Potent and selective inhibitio ...... g with a viral uncoating event

@nl

prefLabel

Potent and selective inhibitio ...... g with a viral uncoating event

@ast

Potent and selective inhibitio ...... g with a viral uncoating event

@en

Potent and selective inhibitio ...... g with a viral uncoating event

@nl

P1433

Q28320362-A02DEF21-4BD5-458D-8271-F3A3085C9C56

P1476

Q28320362-8E560191-E314-47F8-AC3A-23611E20CEB1

P2093

Q28320362-34DD0B12-AF79-4857-B4B5-25F03EE7A099

Q28320362-59ECD5A2-AA81-4C34-B24E-19086F3B1841

Q28320362-6E297B0F-D906-4A40-9F84-7DD187C9FD3E

Q28320362-8F228076-8DA8-425F-9C5F-5799F6E482D9

Q28320362-B344012B-FFFD-4D95-9993-2B82053F34CA

Q28320362-E65EBA9E-0B4C-455A-B54B-19531B11AA98

Q28320362-E841FB51-7948-4DC2-9806-558B47CC1FBF

Q28320362-EE13FAC9-FF67-4FEA-8DEA-308695A97F71

P2860

Q28320362-06B529FD-230E-4BA8-A86B-A23C450D4BCD

Q28320362-09502E93-10E1-47E7-828C-D330E84C2363

Q28320362-0DF499FF-C938-4209-9095-D383405DCD6D

Q28320362-1650821E-68FC-4B99-95E9-9C1DB1B58857

Q28320362-188077D9-9D14-46F9-B6CB-7A42ED6E91B1

Q28320362-19122120-23E7-4C3A-B0DF-F801297077FF

Q28320362-1B218343-03DB-44DB-8FEC-8D1D13D08099

Q28320362-1DA37CA6-8C76-481A-A933-FFA330D17133

Q28320362-2458A652-465E-4D2C-91DC-427295CCC2BF

Q28320362-269B454C-2ED7-407C-B3FA-77BCE86AB9D8

P304

Q28320362-13D3FF5E-D5DD-4A36-884E-E07B2CC128C8

P31

Q28320362-743BCB44-5184-4369-BCAC-2EB8C8CF8AEA

P3181

Q28320362-35BD9D41-DB82-4DA2-AF92-4A4CD775AA99

P356

Q28320362-C89F1B7D-BB2C-4672-BA84-5341C9E23AC8

P407

Q28320362-20EBBF6E-D2B5-462A-BBFC-29361BA4BD52

P433

Q28320362-8B652351-F345-483B-8C58-044B64E18115

P478

Q28320362-938B4761-3B30-4851-8580-A57B259DBC7A

P50

Q28320362-47BC92F4-CE51-47F5-91E2-1E8D96B7C104

Q28320362-7BE7C6C3-719D-4F5C-89AB-08FE10BB303D

P577

Q28320362-1642D4B3-CEB8-4E68-A26A-1749650A43D2

P5875

Q28320362-EF907169-9BF1-4E20-8B60-6C34D7943F75

P698

Q28320362-047F1DAE-C628-430C-853E-6CB4A0373BCC

P921

Q28320362-BAF41A10-05A7-4BB4-940D-6CB612C42C06

P932

Q28320362-CBE51B35-01B7-40E3-A5BA-FCABD5F21C58

P3181

P356

PNAS.89.12.5286

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Potent and selective inhibitio ...... g with a viral uncoating event

@en

P2093

B A Murrer

http://www.w3.org/2001/XMLSchema#string

D Schols

http://www.w3.org/2001/XMLSchema#string

D Schwartz

http://www.w3.org/2001/XMLSchema#string

H Nakashima

http://www.w3.org/2001/XMLSchema#string

M Baba

http://www.w3.org/2001/XMLSchema#string

N Yamamoto

http://www.w3.org/2001/XMLSchema#string

R Pauwels

http://www.w3.org/2001/XMLSchema#string

Z Debyser

http://www.w3.org/2001/XMLSchema#string

P2860

Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin

Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro

Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease

Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS

Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro

Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives

Molecular targets for AIDS therapy

Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor

P304

5286-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

639750

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.89.12.5286

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P50

P577

1992-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

21546669

http://www.w3.org/2001/XMLSchema#string

P698

1608936

http://www.w3.org/2001/XMLSchema#string

P921

P932

49276

http://www.w3.org/2001/XMLSchema#string